Some patients also notice changes in facial volume during weight loss
The results show a 66% reduction in the risk of T2D at three years compared to placebo treatment [52]
The average participant entering Phase 2 Retatrutide trials had a BMI of 37.5, a starting weight around 231 lbs, and the majority carried at least two of the above metabolic risk factors
Carnitine--metabolism and functions
Adverse effects such as tachycardia, infections, headaches, dizziness, nausea, vomiting, diarrhea, and dyspepsia, as well as contraindications such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, hypersensitivity, severe gastrointestinal diseases, renal impairment, and pregnancy have been noted